Compile Data Set for Download or QSAR
Report error Found 34 Enz. Inhib. hit(s) with all data for entry = 11264
TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM603932(US11655243, Example 9 | (+)-trans-Ethyl 2-ethyl-2-...)
Affinity DataKi:  0.200nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
Go to US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM603936(US11655243, Example 13 | (+)-trans-2-Fluoroethyl 2...)
Affinity DataKi:  0.300nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
Go to US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM603935(US11655243, Example 12 | (−)-trans-Fluoromet...)
Affinity DataKi:  0.400nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
Go to US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM603926(US11655243, Example 3 | Ethyl 2-ethyl-2-{[6-{[(1S,...)
Affinity DataKi:  0.5nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
Go to US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM603927(US11655243, Example 4 | Ethyl 2-ethyl-2-{[6-{[(1R,...)
Affinity DataKi:  0.700nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
Go to US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM603938(US11655243, Example 15 | 3-Fluoropropyl 2-ethyl-2-...)
Affinity DataKi:  0.700nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
Go to US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM603938(US11655243, Example 15 | 3-Fluoropropyl 2-ethyl-2-...)
Affinity DataKi:  0.800nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
Go to US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM603952(US11655243, Example 30 | 3-Fluoropropyl 2-ethyl-2-...)
Affinity DataKi:  1.70nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
Go to US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM603947(US11655243, Example 25 | 4-Fluorobutyl 2-ethyl-2-[...)
Affinity DataKi:  1.80nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
Go to US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM603924(US11655243, Example 1 | Ethyl 2-ethyl-2-{[6-({(1S,...)
Affinity DataKi:  1.80nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
Go to US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM603930(US11655243, Example 7 | Ethyl 2-{[6-(cyclopropylme...)
Affinity DataKi:  2.5nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
Go to US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM603925(US11655243, Example 2 | Ethyl 2-ethyl-2-{[6-({(1S,...)
Affinity DataKi:  3.70nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
Go to US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM603928(US11655243, Example 5 | Ethyl 2-ethyl-2-{[6-({(1R,...)
Affinity DataKi:  4.60nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
Go to US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM603933(US11655243, Example 10 | (−)-trans-Ethyl 2-e...)
Affinity DataKi:  8.20nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
Go to US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM603934(US11655243, Example 11 | (−)-trans-Fluoromet...)
Affinity DataKi:  9.70nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
Go to US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM603951(US11655243, Example 29 | 3-Fluoropropyl 2-ethyl-2-...)
Affinity DataKi:  10.9nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
Go to US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM603937(US11655243, Example 14 | (−)-trans-2-Fluoroe...)
Affinity DataKi:  11.4nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
Go to US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM603953(US11655243, Example 31 | (Rac)-trans-3-fluoropropy...)
Affinity DataKi:  11.7nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
Go to US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM603929(US11655243, Example 6 | Ethyl 2-ethyl-2-{[6-({(1R,...)
Affinity DataKi:  13nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
Go to US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM603939(US11655243, Example 16 | 3-Fluoropropyl 2-ethyl-2-...)
Affinity DataKi:  18.8nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
Go to US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM603941(US11655243, Example 18 | N-[(2S)-1-(2-Fluoroethoxy...)
Affinity DataKi:  21nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
Go to US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM603945(US11655243, Example 23 | 3-(p-Tolylsulfonyloxy)pro...)
Affinity DataKi:  21.6nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
Go to US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM603945(US11655243, Example 23 | 3-(p-Tolylsulfonyloxy)pro...)
Affinity DataKi:  65.5nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
Go to US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM603948(US11655243, Example 26 | N-[1-Ethyl-1-[[(1S)-1-(hy...)
Affinity DataKi:  130nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
Go to US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM603931(US11655243, Example 8 | Ethyl 2-ethyl-2-({6-[3-(fl...)
Affinity DataKi:  143nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
Go to US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM603954(US11655243, Example 32 | 3-Fluoropropyl 2-[[6-[[(1...)
Affinity DataKi:  246nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
Go to US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM603940(US11655243, Example 17 | N-[(2S)-1-(2-Fluoroethoxy...)
Affinity DataKi:  331nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
Go to US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM603955(US11655243, Example 33 | Fluoromethyl 2-ethyl-2-[[...)
Affinity DataKi:  348nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
Go to US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM603943(US11655243, Example 20 | 3-Fluoropropyl 2-[6-[[(1S...)
Affinity DataKi:  525nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
Go to US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM603956(US11655243, Example 34 | 2-Fluoroethyl 2-ethyl-2-(...)
Affinity DataKi:  607nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
Go to US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM603944(US11655243, Example 22 | (Rac)-trans-3-Fluoropropy...)
Affinity DataKi:  755nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
Go to US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM603957(US11655243, Example 35 | 3-Fluoropropyl 2-ethyl-2-...)
Affinity DataKi:  1.39E+3nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
Go to US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM603950(US11655243, Example 28 | N-[1-Ethyl-1-[[(1S)-1-(hy...)
Affinity DataKi:  3.95E+3nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
Go to US Patent

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM603949(US11655243, Example 27 | N-[1-Ethyl-1-[[(1S)-1-(hy...)
Affinity DataKi:  4.15E+3nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
Go to US Patent